Pharmaceutical News

RSS

Decision Resources: Rheumatoid arthritis drug market in India to grow up to $672 million in 2013

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in India will more than double by 2013, growing from $296 million in 2008 to $672 million in 2013.

14 Oct 2009

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

Early action, especially rapid rollout of vaccines, is extremely effective in reducing the attack rate of the H1N1 influenza virus, according to a simulation model of a pandemic outbreak reported in a new study in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

14 Oct 2009

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic.

14 Oct 2009

Unapproved codeine sulfate tablets: FDA warns four companies to stop marketing

The U.S. Food and Drug Administration today warned four companies that they must stop marketing unapproved codeine sulfate tablets. These drugs are opioid analgesics, commonly called narcotics, that are widely used to treat pain.

14 Oct 2009

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

An anticancer drug that is commonly used to treat lung and colon malignancies is having a benefit and potentially prolonging survival in patients with invasive bladder cancer, researchers reported at the 2009 Clinical Congress of the American College of Surgeons.

14 Oct 2009

African leaders, Chirac unite to fight fake drug manufacturing, distribution

Leaders from Benin, Burkina Faso, the Central African Republic, Congo-Republic, Niger and Senegal on Monday joined former French President Jacques Chirac in Cotonou, Benin, in a campaign against the manufacturing and sale of fake pharmaceutical products, Reuters reports (Lewis, 10/12).

14 Oct 2009

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Meda Pharmaceuticals Inc. today announced the launch of Onsolis(TM)(fentanyl buccal soluble film) in the U.S. for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

13 Oct 2009

Sequella receives Phase 1 SBIR grant for developing SQ641

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.

13 Oct 2009

Pharmaceuticals to provide safe needle collection and disposal programs for patients

It is illegal in the state of California to unsafely dispose of "sharps" (medical waste such as needles and syringes) in the home, and thanks to California State Senator Joe Simitian's Senate Bill 486, and contributors from his annual "There Oughta Be A Law" contest, 1 million Californians will not be breaking the law anymore (see http://www.ciwmb.ca.gov/hhw/sharps/).

13 Oct 2009

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.

13 Oct 2009

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.

13 Oct 2009

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

People with psoriasis and/or psoriatic arthritis who are taking biologic or non-biologic immunosuppressive medications should receive the inactived forms of both seasonal influenza and H1N1 (swine flu) vaccines as soon as possible, according to a recommendation from the National Psoriasis Foundation.

13 Oct 2009

Simple wound dressings versus antimicrobial dressings

The UK National Health Service could save millions of pounds a year by routinely using inexpensive dressings to treat venous leg ulcers, after a study published in the October issue of BJS showed that they are just as effective as expensive silver dressings in the majority of cases.

13 Oct 2009

SAFC Pharma expands contract manufacturing services

SAFC Pharma®, a business segment of SAFC®, a member of the Sigma-Aldrich® Group, today announced the completion of an addition to its Carlsbad, Calif., facility that expands the Company's contract manufacturing services for its late phase and commercial clients.

13 Oct 2009

Contaminated pre-filled heparin and saline syringes cause bloodstream infections

An outbreak of bloodstream infections appears to have been caused by the contamination of pre-filled heparin and saline syringes made by a single company, according to a report in the October 12 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. The subsequent investigation revealed that the company was not in compliance with safety regulations and identified challenges and areas for improvement in medication monitoring systems.

13 Oct 2009

Health care workers raise troubling concern about H1N1 and seasonal flu vaccines

Hospital workers are asking the same questions about the safety and necessity of flu vaccines as the general public, according to a survey conducted by the American Society of Health-System Pharmacists (ASHP).

13 Oct 2009

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl®1 (triptorelin embonate2 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands.

13 Oct 2009

VitalProteinRx nutritional supplement for chronic kidney disease affected patients

VitalRemedyMD, a physician-established company, offers scientifically formulated integrative nutritional supplements designed to improve the quality of traditional healthcare. "We are proud that VitalProteinRx is now an integral part of Fresenius' armamentarium in helping patients with chronic kidney disease," stated Dr. Seth Baum, Founder of VitalRemedyMD.

13 Oct 2009

Spectrum Pharmaceuticals receives Complete Response letter from the FDA for FUSILEV

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for injection for treatment of patients with advanced metastatic colorectal cancer.

13 Oct 2009

Vanda Pharmaceuticals' Fanapt to be commercialized in the U.S. and Canada by Novartis Pharma

Titan Pharmaceuticals, Inc today announced that Vanda Pharmaceuticals, Inc. reported its entry into an exclusive agreement with Novartis Pharma AG to commercialize and develop Fanapt™ (iloperidone) in the U.S. and Canada. Fanapt™, an atypical anti-psychotic, was approved by the U.S. Food and Drug Administration earlier this summer for the acute treatment of schizophrenia in adults.

13 Oct 2009

Pharmaceutical News

Decision Resources: Rheumatoid arthritis drug market in India to grow up to $672 million in 2013

Rapid rollout of H1N1 vaccines is effective in reducing infection rates according to simulation model

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Unapproved codeine sulfate tablets: FDA warns four companies to stop marketing

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

African leaders, Chirac unite to fight fake drug manufacturing, distribution

Meda Pharmaceuticals introduces Onsolis for treating breakthrough cancer pain

Sequella receives Phase 1 SBIR grant for developing SQ641

Pharmaceuticals to provide safe needle collection and disposal programs for patients

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Psoriasis patients taking immunosuppressive drugs at increased risk of H1N1 flu viruses

Simple wound dressings versus antimicrobial dressings

SAFC Pharma expands contract manufacturing services

Contaminated pre-filled heparin and saline syringes cause bloodstream infections

Health care workers raise troubling concern about H1N1 and seasonal flu vaccines

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

VitalProteinRx nutritional supplement for chronic kidney disease affected patients

Spectrum Pharmaceuticals receives Complete Response letter from the FDA for FUSILEV

Vanda Pharmaceuticals' Fanapt to be commercialized in the U.S. and Canada by Novartis Pharma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News